Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2013
08/22/2013US20130216585 Composition and methods for quenching free radicals and modulating inflammation
08/22/2013US20130216574 Kit providing multiple unmet therapeutic effects
08/22/2013US20130216554 Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin
08/22/2013US20130216552 Crth2 modulators
08/22/2013US20130216550 Breast cancer therapeutics
08/22/2013US20130216545 Early Diagnosis and Novel Treatment of Cancer
08/22/2013US20130216531 Anti-cxcr4 as a sensitizer to cancer therapeutics
08/22/2013US20130216530 Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants
08/22/2013US20130216524 Predictors for Cancer Treatment
08/22/2013US20130216523 Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
08/22/2013US20130216521 Dietary supplement for enhancing animal health
08/22/2013US20130216520 Processing biomass
08/22/2013US20130216512 Stable aqueous suspension
08/22/2013US20130216500 Method of treating or retarding the development of blindness
08/22/2013US20130216498 Imidazopyridine derivatives as jak inhibitors
08/22/2013US20130216497 Novel tricyclic compounds
08/22/2013US20130216494 Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof
08/22/2013US20130216493 Peg or peg block copolymers for treating colorectal cancer
08/22/2013US20130216492 Method for Searching for Malodor Control Agent, Malodor Control Agent, and Malodor Control Method
08/22/2013US20130216476 Use of an anti-cd71 antibody for preparing a medicament
08/22/2013US20130213851 Omega 3 fatty acid formulations
08/22/2013DE112012000221T5 Extrakte aus Cynanchum sp. Extracts of Cynanchum sp. und darin enthaltene Wirkstoffe zur Behandlung von Arthritis and active ingredients contained therein for the treatment of arthritis
08/22/2013DE112010001992T5 Verfahren und Zusammensetzung zur Bekämpfung von Ektoparasiten A method and composition for controlling ectoparasites
08/22/2013DE102012101248A1 Acylhydrazone und ihre Verwendung zur Vermeidung der Ausbildung oder zur Aufhebung von Resistenzen von Tumoren gegen Zytostatika Acylhydrazones and their use to avoid the formation or to the annulment of resistance of tumors to cytotoxic drugs
08/22/2013DE102012003541A1 Bacterial nanocellulose body useful e.g. as transplant for in situ cell colonization and tissue formation, comprises channel-like pore structure, interconnecting multidimensional structure, and channel-shaped cavities with open cell wall
08/22/2013DE102012003286A1 Kombination aus Lipidtransferproteinen und Phenolderivate enthaltenden Pflanzenstoffen mit lokal-mucosaler Effizienz Combination of lipid transfer proteins and phenolic derivatives containing plant materials with locally-mucosal efficiency
08/21/2013EP2628800A1 MicroRNA (miRNA) miR-21 for diagnostic and therapeutic purposes
08/21/2013EP2628799A2 RNAi modulation of RSV and therapeutic uses thereof
08/21/2013EP2628798A1 Prophylactic or therapeutic agent for fibrosis
08/21/2013EP2628754A1 Method for producing and using a copolymer of sodium carboxymethyl cellulose and gossypol
08/21/2013EP2628741A2 Novel compound of a reverse-turn mimetic and a production method and use therefor
08/21/2013EP2628738A1 Heterocyclic substituted pyridine derivatives and antifungal agent containing same
08/21/2013EP2628737A1 Hypocholesterolemic, anti-inflammatory and antiepileptic neuroprotective compound
08/21/2013EP2628733A1 Acylbenzene derivative
08/21/2013EP2628732A1 Novel crystalline form of rilpivirine hydrochloride
08/21/2013EP2628727A2 Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
08/21/2013EP2628726A1 Hydroxamate-based inhibitors of deacetylases b
08/21/2013EP2628725A1 Prostaglandins and analogues as agents for lowering intraocular pressure
08/21/2013EP2628724A1 Aryloxyurea compound and pest control agent
08/21/2013EP2628506A1 Antimicrobially active composition having a content of bispyridinium alkane (octenidine dihydrochloride)
08/21/2013EP2628485A1 New use of chemical ingredients in cynomorium as phytoestrogen
08/21/2013EP2628482A1 Rho kinase inhiitors for use in the treatment of neuroblastoma
08/21/2013EP2628481A1 Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV
08/21/2013EP2628480A1 Compounds and pharmaceutical compositions thereof for inhibiting mammalian tumor cell proliferation
08/21/2013EP2627769A2 Nucleic acid modulators of clec-2
08/21/2013EP2627665A1 Methods and compositions for treating hemophilia b
08/21/2013EP2627657A2 Molecular containers and methods of making and using same
08/21/2013EP2627656A1 Process for manufacturing dihydropteridinones and intermediates thereof
08/21/2013EP2627655A2 Therapeutic 5,6,5-tricyclic analogs
08/21/2013EP2627653A1 3 -amino- pyrazole derivatives useful against tuberculosis
08/21/2013EP2627652A2 Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof
08/21/2013EP2627649A1 Cxcr4 receptor antagonists
08/21/2013EP2627648A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
08/21/2013EP2627641A1 Reversal of drug-induced neuromuscular block using novel molecular containers
08/21/2013EP2627638A1 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
08/21/2013EP2627637A1 N-pyridin-3-yl or n-pyrazin-2-yl carboxamides
08/21/2013EP2627635A1 Salts of arylsulfonamide ccr3 antagonists
08/21/2013EP2627632A1 Sulphonamide compounds and methods of making and using same
08/21/2013EP2627631A1 Pyrrolidinones as metap2 inhibitors
08/21/2013EP2627630A1 Serotonin reuptake inhibitors
08/21/2013EP2627341A2 Coriolus versicolor extracts, methods of preparation and uses thereof
08/21/2013EP2627340A1 A method of regulating plasma lipoproteins
08/21/2013EP2627339A1 A modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy
08/21/2013EP2627338A1 Axl receptor tyrosine kinase aptamer inhibitor for use in therapy
08/21/2013EP2627337A1 Egfr aptamer inhibitor for use in therapy and diagnosis
08/21/2013EP2627336A1 Method for treating cystic fibrosis with inhaled denufosol
08/21/2013EP2627335A1 Composition for skin treatment
08/21/2013EP2627334A1 Methods and compositions for inhibition of polymerase
08/21/2013EP2627333A1 Combination treatment of cancer
08/21/2013EP2627332A2 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
08/21/2013EP2627331A1 Methods for treating hyperuricemia and related diseases
08/21/2013EP2627330A2 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
08/21/2013EP2627329A1 Trpa1 receptor antagonist
08/21/2013EP2627328A1 Combinations of serotonin receptor agonists for treatment of movement disorders
08/21/2013EP2627327A1 Novel triterpene derivatives
08/21/2013EP2627326A2 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
08/21/2013EP2627325A1 Pharmaceutical composition
08/21/2013EP2627324A2 Substituted benzamides and their uses
08/21/2013EP2627323A1 Antitussive compositions comprising memantine
08/21/2013EP2627322A1 Methods of treating giardiasis
08/21/2013EP2627321A1 Treatment of cancer/inhibition of metastasis
08/21/2013EP2627319A1 Pharmaceutical compositions containing a dgat1 inhibitor
08/21/2013EP2627317A2 Aggregate nanoparticulate medicament formulations, manufacture and use thereof
08/21/2013EP2627316A1 Pharmaceutical formulation for histone deacetylase inhibitors
08/21/2013EP2627315A1 Composition for treating cancer by the controlled release of an active substance
08/21/2013EP2627309A2 Use of monoamine oxidase inhibitors to improve epithelial biology
08/21/2013EP2627200A1 Food supplement
08/21/2013EP2627199A1 Coffee extracts as ingredients of foods, drugs, cosmetics, dietary supplements, and biologics
08/21/2013EP2627195A1 Curcuminoid solid dispersion formulation
08/21/2013EP2627182A1 Metal complexes of n-heterocyclic carbenes
08/21/2013EP2627181A2 Heteroaryls and uses thereof
08/21/2013EP2627179A1 Methods for inhibiting cell proliferation in egfr-driven cancers
08/21/2013EP2627173A1 Clevidipine emulsion formulations containing antimicrobial agents
08/21/2013EP2379497B1 Hemifumarate salt of 1- ý4- ý1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl¨-2 -ethyl-benzyl¨-a zetidine-3-carboxylic acid
08/21/2013EP2358717B1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
08/21/2013EP2143437B1 Compositions and methods for the diagnosis and treatment of tumor
08/21/2013CN1976921B Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
08/21/2013CN1757622B 2-hydroxy-3-alkoxypropyl sulfides, sulfones, and sulfoxides: new surface active agents
08/21/2013CN1533374B Substitutled cyclohexane-1,4-diamine derivatives
08/21/2013CN103261895A Tyrosine-phosphorylated wbp2, a novel cancer target and biomarker
1 ... 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 ... 7860